LivaNova (LIVN) Expected to Announce Quarterly Earnings on Wednesday

LivaNova (NASDAQ:LIVN) is projected to issue its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of $0.80 per share and revenue of $354.3120 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 8:00 AM ET.

LivaNova Trading Down 0.1%

NASDAQ LIVN opened at $68.35 on Tuesday. The firm’s fifty day moving average price is $64.14 and its 200 day moving average price is $58.59. LivaNova has a 12 month low of $32.48 and a 12 month high of $69.31. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.33 and a quick ratio of 1.12. The company has a market capitalization of $3.73 billion, a price-to-earnings ratio of -17.09 and a beta of 0.97.

Hedge Funds Weigh In On LivaNova

A number of large investors have recently bought and sold shares of LIVN. iSAM Funds UK Ltd purchased a new position in LivaNova in the third quarter worth $218,000. Mackenzie Financial Corp purchased a new stake in shares of LivaNova during the 4th quarter worth $212,000. Headlands Technologies LLC boosted its position in shares of LivaNova by 270.8% during the 2nd quarter. Headlands Technologies LLC now owns 3,456 shares of the company’s stock worth $156,000 after purchasing an additional 2,524 shares in the last quarter. Northwestern Mutual Wealth Management Co. acquired a new position in shares of LivaNova during the 4th quarter worth $145,000. Finally, Strs Ohio purchased a new position in shares of LivaNova in the 1st quarter valued at about $130,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on LIVN shares. Barclays upped their price objective on shares of LivaNova from $58.00 to $67.00 and gave the company an “equal weight” rating in a research note on Friday, January 9th. The Goldman Sachs Group restated a “neutral” rating and set a $66.00 price target on shares of LivaNova in a research note on Friday, January 9th. Piper Sandler reaffirmed an “overweight” rating and set a $85.00 price target on shares of LivaNova in a research report on Thursday. KeyCorp assumed coverage on LivaNova in a research note on Friday, December 19th. They issued an “overweight” rating and a $81.00 price objective for the company. Finally, Wall Street Zen upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 20th. Seven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, LivaNova has a consensus rating of “Moderate Buy” and a consensus price target of $71.11.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.